MARKET

AMGN

AMGN

Amgen Inc
NASDAQ
283.74
+0.34
+0.12%
Pre Market: 282.29 -1.45 -0.51% 08:03 11/28 EST
OPEN
281.95
PREV CLOSE
283.40
HIGH
285.57
LOW
281.41
VOLUME
106
TURNOVER
--
52 WEEK HIGH
296.67
52 WEEK LOW
192.56
MARKET CAP
151.40B
P/E (TTM)
22.73
1D
5D
1M
3M
1Y
5Y
Possible bearish signals as Amgen Inc. (NASDAQ:AMGN) insiders disposed of US$5.2m worth of stock
The fact that multiple Amgen Inc. ( NASDAQ:AMGN ) insiders offloaded a considerable amount of shares over the past year...
Simply Wall St. · 4d ago
AMGEN ANNOUNCES WEBCAST OF 2022 EVERCORE ISI HEALTHCARE CONFERENCE
Amgen (NASDAQ:AMGN) will present at the Evercore ISI HealthCONx Conference at 11:20 a.m. ET on Tuesday, November 29, 2022. David M. Reese, M.D., executive vice president of Research and Development at Amgen will present at the conference. The webcast will ...
PR Newswire · 4d ago
Chevron, Amgen share losses contribute to Dow's 50-point fall
Marketwatch.com · 4d ago
Amneal Pharmaceuticals Launches Releuko for Neutropenia in US
Amneal Pharmaceuticals Launches Releuko for Neutropenia in US
MT Newswires · 5d ago
FDA Investigating Risk Of Severe Hypocalcemia In Patients On Dialysis Receiving Osteoporosis Medicine Prolia (denosumab)
Benzinga · 6d ago
Amgen's Osteoporosis Drug Prolia Faces US FDA Probe Over Risk of Severe Hypocalcemia in Dialysis Patients
Amgen's Osteoporosis Drug Prolia Faces US FDA Probe Over Risk of Severe Hypocalcemia in Dialysis Patients
MT Newswires · 6d ago
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks · 11/21 14:00
Amgen Inc. (NASDAQ:AMGN) is largely controlled by institutional shareholders who own 78% of the company
To get a sense of who is truly in control of Amgen Inc. ( NASDAQ:AMGN ), it is important to understand the ownership...
Simply Wall St. · 11/20 14:00
More
About AMGN
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Webull offers kinds of Amgen, Inc. stock information, including NASDAQ:AMGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMGN stock methods without spending real money on the virtual paper trading platform.